One study found that about 67% of patients taking Structure Therapeutics’s pill lost over 6% of their weight and about 33% ...
(Adds shares in paragraph 6, investor comment in paragraph 7) By Maggie Fick LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and ...
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...
(Reuters) – Structure Therapeutics said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations and sending shares ...
Structure Therapeutics’ American depositary receipts gained more than 6% premarket on Monday after the company said its ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug. Patients taking Novo Nordisk's obesity drug Wegovy ...